HCC Stock Recent News

BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company received approval from the National Medical Products Administration (NMPA) in China to proceed with a pivotal trial to evaluate amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab, the current standard of care, versus the standard of care alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC).

EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgent need for new treatment options The multiple regulatory designations were granted following strong positive results from a global randomized Phase 1b/2 study in first-line HCC demonstrating superior outcomes for amezalpat combination therapy across multiple study endpoints, including overall survival in both the entire population and key subpopulations, when compared to standard of care alone BRISBANE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to amezalpat (TPST-1120), an oral, small molecule, selective PPAR⍺ antagonist for the treatment of patients with hepatocellular carcinoma

This campaign aims to raise awareness of the high-quality care and services provided by Susan G. Komen to improve and save the lives of those impacted by breast cancer This campaign aims to raise awareness of the high-quality care and services provided by Susan G. Komen to improve and save the lives of those impacted by breast cancer

PITTSBURGH--(BUSINESS WIRE)-- #Innovation--Somerset International has successfully deployed six state-of-the-art Tailings Dewatering systems at Warrior Met Coal's Blue Creek Mine.

Thermal coal may retire for good in the U.S., but metallurgical coal could see “healthy” growth, says analyst.

MORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it has entered into a binding letter of intent (“LOI”) with New Day Diagnostics LLC to in-license diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC). The celiac, respiratory multiplex and H. pylori tests have CE marks and are eligible to be sold in Europe at the present time.

Warrior Met Coal's strong margins and strategic location contribute to its resilience, with only a 12% stock price decline this year compared to peers' 30-40% drop. Q1 2025 results showed a weak performance, with $39M adjusted EBITDA and negative $68M free cash flow due to soft coking coal prices. Despite weak market conditions, Warrior's liquidity is robust with $617M available, ensuring coverage for Blue Creek's remaining capex and potential losses.

Warrior Met Coal, Inc. (NYSE:HCC ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Brian Chopin - Chief Accounting Officer and Controller Walter Scheller - Chief Executive Officer Dale Boyles - Chief Financial Officer Conference Call Participants Katja Jancic - BMO Capital Markets Nick Giles - B. Riley Securities George Eady - UBS Nathan Martin - The Benchmark Company Operator Good afternoon, my name is Dhawan, and I will be your conference operator today.

Warrior Met Coal (HCC) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $2.63 per share a year ago.

BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (NYSE: HCC) (“Warrior” or the “Company”) today announced results for the first quarter of 2025. Warrior is the leading dedicated U.S.-based producer and exporter of high-quality steelmaking coal for the global steel industry. Warrior reported a net loss for the first quarter of 2025 of $8.2 million, or $0.16 per diluted share, a decrease from net income of $137.0 million, or $2.62 per diluted share, in the first quarter of 2024. The Compa.